Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Advances in Therapy|October 19, 2023
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug LabelsDaria Piacentino, Ajay Ogirala, Robert Lew, et al.
Diabetes, Obesity & Metabolism|March 27, 2024
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetesSnežana Milanović, Nina Dedic, Robert Lew, et al.
International Clinical Psychopharmacology|March 16, 2021
Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trialLenard A Adler, Robert Goldman, Seth C Hopkins, et al.
The New England Journal of Medicine|April 16, 2020
A Non-D2-Receptor-Binding Drug for the Treatment of SchizophreniaKenneth S Koblan, Justine Kent, Seth C Hopkins, et al.
Clinical Drug Investigation|November 25, 2015
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in AdultsSeth C Hopkins, Soujanya Sunkaraneni, Estela Skende, et al.
Clinical Pharmacology and Therapeutics|May 7, 2021
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood DisordersSeth C Hopkins, Scott Wilkinson, Taryn J Corriveau, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 8, 2015
Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in AdultsKenneth S Koblan, Seth C Hopkins, Kaushik Sarma, et al.
NPJ Schizophrenia|December 10, 2021
Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension studyChristoph U Correll, Kenneth S Koblan, Seth C Hopkins, et al.
Drug Metabolism and Bioanalysis Letters|January 7, 2026
A Physiologically-Based Pharmacokinetic Model to Characterize Dasotraline Pharmacokinetics and CYP-mediated Drug-Drug InteractionsGuangqing Xiao, Jing Lin, Yu-Luan Chen, et al.
European Journal of Pharmacology|July 19, 2011
Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidemChristiaan H Vinkers, Berend Olivier, Taleen Hanania, et al.
Pageof 6